Diabetic Retinopathy Market, By Disease Type (Proliferative Diabetic Retinopathy and Non-proliferative Diabetic Retinopathy), By Treatment Type (Anti-Vascular Endothelial Growth Factor Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy, and

Diabetic Retinopathy Market, By Disease Type (Proliferative Diabetic Retinopathy and Non-proliferative Diabetic Retinopathy), By Treatment Type (Anti-Vascular Endothelial Growth Factor Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy, and Others), By Route of Administration (Intravitreal Injections, Intravitreal Implants, Oral, Topical Eye Drops, Laser Surgery, and Others), By End User (Hospitals, Ophthalmology Clinics, Ambulatory Surgery Centers, Long-Term Care Centers, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Diabetic retinopathy is a medical condition in which damage occurs to the retina due to complications of diabetes mellitus. High blood sugar levels associated with diabetes can damage blood vessels inside the retina. Diabetic retinopathy occurs in both type 1 and type 2 diabetes and is a leading cause of blindness among working-age adults. The global diabetic retinopathy market is driven by rising prevalence of diabetes, increasing awareness regarding diabetic retinopathy diagnosis and treatment, and the availability of advanced retinal screening techniques. However, high cost of treatment and inadequate reimbursement policies limit the market growth.

Market Dynamics:

High cost of retinal screening, drugs, and surgeries, shortage of ophthalmologists in developing nations, and inadequate insurance coverage in some countries are expected to restrain the market growth. Key opportunity lies in development of cost-effective screening solutions, combinational therapeutics, and artificial intelligence-powered analytic platforms to detect diabetic retinopathy faster and more accurately.

Key Features of the Study:

• This report provides in-depth analysis of the global diabetic retinopathy market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031, considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global diabetic retinopathy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis AG, Bayer AG, Regeneron Pharmaceuticals Inc., Roche Holding AG, Allergan PLC, Zeiss International, Topcon Corporation, Heidelberg Engineering GmbH, Optos PLC, Canon Inc., Nidek Co., Ltd., Ellex Medical Lasers Limited, Bausch + Lomb Incorporated, Abbott Laboratories, and Santen Pharmaceutical Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global diabetic retinopathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Market Segmentation

• By Disease Type Insights (Revenue, USD Bn, 2019 - 2031)
• Proliferative Diabetic Retinopathy
• Non-proliferative Diabetic Retinopathy
• By Treatment Type Insights (Revenue, USD Bn, 2019 - 2031)
• Anti-Vascular Endothelial Growth Factor Therapy
• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy
• Others (Intraocular Corticosteroids, etc.)
• By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
• Intravitreal Injections
• Intravitreal Implants
• Oral
• Topical Eye Drops
• Laser Surgery
• Others
• By End User Insights (Revenue, USD Bn, 2019 - 2031)
• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgery Centers
• Long-Term Care Centers
• Others
• By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Novartis AG
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• Roche Holding AG
• Allergan PLC
• Zeiss International
• Topcon Corporation
• Heidelberg Engineering GmbH
• Optos PLC
• Canon Inc.
• Nidek Co., Ltd.
• Ellex Medical Lasers Limited
• Bausch + Lomb Incorporated
• Abbott Laboratories
• Santen Pharmaceutical Co., Ltd.